This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Wednesday, June 21 • 10:30am - 11:45am
#316: Quantitative Metrics to Capture the Value of Patient Engagement

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-569-L04-P; CME 1.25; IACET 1.25; RN 1.25

There is growing agreement among stakeholders in the medical products life cycle that patient engagement is key to assuring that patient needs, including improved patient outcomes, are met. The moral, ethical, and pragmatic reasons for patient engagement are widely accepted, but research sponsors must understand the impact of patient engagement on the performance of important studies and are often faced with the need to demonstrate its value before allocating resources, both personnel and financial, to implementation. Understanding return on investment, or “return on engagement (ROE),” is complicated by the availability of many different types of patient engagement efforts that could be employed and the lack of information about their value in a given context.

Presenters in this session will discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.

Learning Objectives

Discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.


Kenneth A. Getz, MBA


Defining Metrics for ROE of Patient-Centric Initiatives Across the Product Life Cycle
Stella Stergiopoulos, MPH, MS

Getting Down to the Bottom Line: Measuring the Financial Impact of Patient Engagement
Bennett Levitan, MD, PhD

Update on the PFMD: Landscape of Patient-Centric Initiatives
Marc M. Boutin, JD

avatar for Marc Boutin

Marc Boutin

Chief Executive Officer, National Health Council (NHC)
the CEO of the National Health Council.Boutin has been a leading voice for greater patient involvement, starting with the development of new drugs to regulatory oversight of health care delivery. Under his leadership, the NHC has convened a broad range of stakeholders to effectiv... Read More →
avatar for Kenneth Getz

Kenneth Getz

Director of Sponsored Research Programs and Associate Professor, Center For the Study of Drug Development, Tufts University School of Medicine
Mr. Getz is an internationally recognized expert on drug development management practices and trends. His research on protocol design complexity, clinical research efficiency, and on outsourcing and site management practices -- conducted over the past three decades -- are widely... Read More →
avatar for Bennett Levitan

Bennett Levitan

Senior Director, Benefit-Risk Assessment, Department of Epidemiology, Janssen Research & Development, LLC
Bennett Levitan, MD-PhD is Senior Director, Dept of Epidemiology at Janssen R&D. He introduced state of the art patient-focused benefit-risk assessment to Janssen and has led numerous teams in preparation of benefit-risk assessments. He co-led development of the PhRMA BRAT Framew... Read More →
avatar for Stella Stergiopoulos

Stella Stergiopoulos

Senior Research Project Manager, Tufts Center for the Study of Drug Development
Ms. Stella Stergiopoulos manages multi-sponsored and grant funded research projects at Tufts CSDD. She has experience conducting research on pharmaceutical industry practices and trends affecting pharmacovigilance, non-clinical drug development, pharmaceutical outsourcing practic... Read More →

Wednesday June 21, 2017 10:30am - 11:45am
N426a McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616